| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
|
Vlaar, Alexander P J
|
|
|
2 |
12 |
p. e764-e773
|
artikel
|
| 2 |
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study
|
Webb, Brandon J
|
|
|
2 |
12 |
p. e754-e763
|
artikel
|
| 3 |
COVID-19 and African rheumatology: progress in adversity
|
Akintayo, Richard O
|
|
|
2 |
12 |
p. e732-e734
|
artikel
|
| 4 |
Defining the scourge of COVID-19 hyperinflammatory syndrome
|
Cron, Randy Q
|
|
|
2 |
12 |
p. e727-e729
|
artikel
|
| 5 |
Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians
|
Schreiber, Karen
|
|
|
2 |
12 |
p. e735-e736
|
artikel
|
| 6 |
Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?
|
Zizzo, Gaetano
|
|
|
2 |
12 |
p. e779-e790
|
artikel
|
| 7 |
New lessons for an old problem: ASSET open-label extension
|
Del Galdo, Francesco
|
|
|
2 |
12 |
p. e726-e727
|
artikel
|
| 8 |
Optimal length and usefulness of temporal artery biopsies in the diagnosis of giant cell arteritis: a 10-year retrospective review of medical records
|
Chu, Raymond
|
|
|
2 |
12 |
p. e774-e778
|
artikel
|
| 9 |
Optimal temporal artery biopsy length for diagnosis of giant cell arteritis
|
Buttgereit, Frank
|
|
|
2 |
12 |
p. e730-e732
|
artikel
|
| 10 |
Research in Brief
|
Thorley, Jennifer
|
|
|
2 |
12 |
p. e742
|
artikel
|
| 11 |
Rheumatology care in prisons: cruel and unusual punishment?
|
The Lancet Rheumatology,
|
|
|
2 |
12 |
p. e725
|
artikel
|
| 12 |
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial
|
Chung, Lorinda
|
|
|
2 |
12 |
p. e743-e753
|
artikel
|
| 13 |
Serious infection with tofacitinib in patients with rheumatoid arthritis: the importance of context
|
Rivas, Jose L
|
|
|
2 |
12 |
p. e738
|
artikel
|
| 14 |
The Lazarus effect of very high-dose intravenous anakinra in severe non-familial CNS-HLH
|
Kavirayani, Akhila
|
|
|
2 |
12 |
p. e736-e738
|
artikel
|
| 15 |
The opening salvo of anti-complement therapy against COVID-19
|
Campbell, Courtney M
|
|
|
2 |
12 |
p. e729-e730
|
artikel
|
| 16 |
Tocilizumab in COVID-19: finding the optimal route and dose
|
Jain, Siddharth
|
|
|
2 |
12 |
p. e738-e739
|
artikel
|
| 17 |
Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply
|
Guaraldi, Giovanni
|
|
|
2 |
12 |
p. e739-e740
|
artikel
|
| 18 |
Tofacitinib approved for arthritis treatment in children
|
Owens, Brian
|
|
|
2 |
12 |
p. e741
|
artikel
|
Tijdschrift beschrijving